# tables/adverse-events/aet01.qmd development

    Code
      print(data_snap[[i]])
    Output
                                                                    A: Drug X    B: Placebo   C: Combination
                                                                     (N=134)      (N=134)        (N=132)    
      ——————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                100 (74.6%)   98 (73.1%)    103 (78.0%)  
      Total number of AEs                                              502          480            604      
      Total number of deaths                                       25 (18.7%)    23 (17.2%)     22 (16.7%)  
      Total number of patients withdrawn from study due to an AE    3 (2.2%)      6 (4.5%)       5 (3.8%)   
      Total number of patients with at least one                                                            
        AE with fatal outcome                                       5 (3.7%)      5 (3.7%)       6 (4.5%)   
        Serious AE                                                 85 (63.4%)    80 (59.7%)     87 (65.9%)  
        Serious AE leading to withdrawal from treatment             6 (4.5%)     12 (9.0%)       9 (6.8%)   
        Serious AE leading to dose modification/interruption       36 (26.9%)    40 (29.9%)     47 (35.6%)  
        Related Serious AE                                         64 (47.8%)    52 (38.8%)     64 (48.5%)  
        AE leading to withdrawal from treatment                    20 (14.9%)    24 (17.9%)     26 (19.7%)  
        AE leading to dose modification/interruption               63 (47.0%)    70 (52.2%)     77 (58.3%)  
        Related AE                                                 86 (64.2%)    85 (63.4%)     92 (69.7%)  
        Related AE leading to withdrawal from treatment             10 (7.5%)     9 (6.7%)      12 (9.1%)   
        Related AE leading to dose modification/interruption       44 (32.8%)    44 (32.8%)     51 (38.6%)  
        Severe AE (at greatest intensity)                          77 (57.5%)    70 (52.2%)     79 (59.8%)  

---

    Code
      print(data_snap[[i]])
    Output
                                                                    A: Drug X    B: Placebo   C: Combination
                                                                     (N=134)      (N=134)        (N=132)    
      ——————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                100 (74.6%)   98 (73.1%)    103 (78.0%)  
      Total number of AEs                                              502          480            604      
      Total number of deaths                                       25 (18.7%)    23 (17.2%)     22 (16.7%)  
      Total number of patients withdrawn from study due to an AE    3 (2.2%)      6 (4.5%)       5 (3.8%)   
      Total number of patients with at least one                                                            
        AE with fatal outcome                                       5 (3.7%)      5 (3.7%)       6 (4.5%)   
        Serious AE                                                 85 (63.4%)    80 (59.7%)     87 (65.9%)  
        Serious AE leading to withdrawal from treatment             6 (4.5%)     12 (9.0%)       9 (6.8%)   
        Serious AE leading to dose modification/interruption       36 (26.9%)    40 (29.9%)     47 (35.6%)  
        Related Serious AE                                         64 (47.8%)    52 (38.8%)     64 (48.5%)  
        AE leading to withdrawal from treatment                    20 (14.9%)    24 (17.9%)     26 (19.7%)  
        AE leading to dose modification/interruption               63 (47.0%)    70 (52.2%)     77 (58.3%)  
        Related AE                                                 86 (64.2%)    85 (63.4%)     92 (69.7%)  
        Related AE leading to withdrawal from treatment             10 (7.5%)     9 (6.7%)      12 (9.1%)   
        Related AE leading to dose modification/interruption       44 (32.8%)    44 (32.8%)     51 (38.6%)  
        Grade 3-5 AE                                               90 (67.2%)    83 (61.9%)     93 (70.5%)  
      Total number of patients with at least one                                                            
        C.1.1.1.3/B.2.2.3.1 AESI (BROAD)                           58 (43.3%)    60 (44.8%)     66 (50.0%)  
        SMQ 02 Reference Name                                           0            0              0       
        D.2.1.5.3/A.1.1.1.1 AESI                                   62 (46.3%)    61 (45.5%)     76 (57.6%)  

---

    Code
      print(data_snap[[i]])
    Output
                                                                    A: Drug X    B: Placebo   C: Combination
                                                                     (N=134)      (N=134)        (N=132)    
      ——————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                100 (74.6%)   98 (73.1%)    103 (78.0%)  
      Total number of AEs                                              502          480            604      
      Total number of deaths                                       25 (18.7%)    23 (17.2%)     22 (16.7%)  
      Total number of patients withdrawn from study due to an AE    3 (2.2%)      6 (4.5%)       5 (3.8%)   
      Total number of patients withdrawn informed consent           1 (0.7%)      1 (0.7%)       1 (0.8%)   
      Total number of patients with at least one                                                            
        AE with fatal outcome                                       5 (3.7%)      5 (3.7%)       6 (4.5%)   
        Serious AE                                                 85 (63.4%)    80 (59.7%)     87 (65.9%)  
        AE leading to withdrawal from treatment                    20 (14.9%)    24 (17.9%)     26 (19.7%)  
        Related AE                                                 86 (64.2%)    85 (63.4%)     92 (69.7%)  
        Grade 3-5 AE                                               90 (67.2%)    83 (61.9%)     93 (70.5%)  
        Grade 4/5 AE                                               77 (57.5%)    70 (52.2%)     79 (59.8%)  

---

    Code
      print(data_snap[[i]])
    Output
                                                                    A: Drug X    B: Placebo   C: Combination
                                                                     (N=134)      (N=134)        (N=132)    
      ——————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one AE                100 (74.6%)   98 (73.1%)    103 (78.0%)  
      Total number of AEs                                              502          480            604      
      Total number of deaths                                       25 (18.7%)    23 (17.2%)     22 (16.7%)  
      Total number of patients withdrawn from study due to an AE    3 (2.2%)      6 (4.5%)       5 (3.8%)   
      Total number of patients with at least one                                                            
        AE with fatal outcome                                       5 (3.7%)      5 (3.7%)       6 (4.5%)   
        Serious AE                                                 85 (63.4%)    80 (59.7%)     87 (65.9%)  
        AE leading to withdrawal from treatment                    20 (14.9%)    24 (17.9%)     26 (19.7%)  
        AE leading to dose modification/interruption               63 (47.0%)    70 (52.2%)     77 (58.3%)  
        Related AE                                                 86 (64.2%)    85 (63.4%)     92 (69.7%)  
        Grade 3-5 AE                                               90 (67.2%)    83 (61.9%)     93 (70.5%)  
      Total number of unique preferred terms which are                                                      
        Serious AE                                                      4            4              4       
        AE leading to dose modification/interruption                   10            10             10      
        Related AE                                                      5            5              5       
        Grade 3-5 AE                                                    5            5              5       
        Grade 4/5 AE                                                    3            3              3       
      Total number of adverse events which are                                                              
        Serious AE                                                     204          194            245      
        AE leading to dose modification/interruption                   123          135            158      
        Related AE                                                     231          231            290      
        Grade 3-5 AE                                                   249          229            277      
        Grade 4/5 AE                                                   143          134            168      

